The toxicity and distribution of iron oxide-zinc oxide core-shell nanoparticles in C57BL/6 mice after repeated subcutaneous administration

Jun Won Yun, Jung Hee Yoon, Byeong Cheol Kang, Nam Hyuk Cho, Seung Hyeok Seok, Seung Kee Min, Ji Hyun Min, Jeong Hwan Cho, Young-geun Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Therapeutic cancer vaccines promote immune responses by delivering tumour-specific antigens. Recently, we developed iron oxide (Fe3O4)-zinc oxide (ZnO) core-shell nanoparticles (CSNPs) as carriers for antigen delivery into dendritic cells (DCs), and the CSNPs were injected subcutaneously into C57BL/6 mice to examine the systemic toxicity, tissue distribution and excretion of the CSNPs. The doses injected were 0, 4, 20 and 200mgkg-1 weekly for 4weeks. No significant changes were observed after the CSNPs administration with respect to mortality, clinical observations, body weight, food intake, water consumption, urinalysis, haematology, serum biochemistry,and organ weights. A dose-dependent increase in granulomatous inflammation was observed at the injection site of the CSNP-treated animals, but no other histopathological lesions in other organs could be attributed to the CSNPs. The Zn concentration, which is an indicator for CSNPs, was not significantly higher in the sampled tissues, urine, or faeces after the CSNP injection. In contrast, the Zn concentration at the subcutaneous skin of the site injected with the CSNPs increased in a dose-dependent manner, along with a macroscopic deposition of the CSNPs. The CSNP residue at the injection site resulted in a foreign body response with the appearance of macrophage infiltration, but otherwise did not show any systemic distribution or toxicity at up to 200mgkg-1 during this study. In conclusion, CSNPs could be used as good antigen carriers for DC-based immunotherapy, although further study is needed to completely clear the residue of the CSNPs at the injection site.

Original languageEnglish
Pages (from-to)593-602
Number of pages10
JournalJournal of Applied Toxicology
Volume35
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1

Fingerprint

Zinc Oxide
Inbred C57BL Mouse
Nanoparticles
Toxicity
Injections
Antigens
ferric oxide
Dendritic Cells
Tissue
Cancer Vaccines
Biochemistry
Urinalysis
Organ Size
Macrophages
Neoplasm Antigens
Hematology
Tissue Distribution
Foreign Bodies
Infiltration
Feces

Keywords

  • Distribution
  • Excretion
  • Iron oxide-zinc oxide core-shell nanoparticles
  • Nanoparticle
  • Toxicity

ASJC Scopus subject areas

  • Toxicology

Cite this

The toxicity and distribution of iron oxide-zinc oxide core-shell nanoparticles in C57BL/6 mice after repeated subcutaneous administration. / Yun, Jun Won; Yoon, Jung Hee; Kang, Byeong Cheol; Cho, Nam Hyuk; Seok, Seung Hyeok; Min, Seung Kee; Min, Ji Hyun; Cho, Jeong Hwan; Kim, Young-geun.

In: Journal of Applied Toxicology, Vol. 35, No. 6, 01.06.2015, p. 593-602.

Research output: Contribution to journalArticle

Yun, Jun Won ; Yoon, Jung Hee ; Kang, Byeong Cheol ; Cho, Nam Hyuk ; Seok, Seung Hyeok ; Min, Seung Kee ; Min, Ji Hyun ; Cho, Jeong Hwan ; Kim, Young-geun. / The toxicity and distribution of iron oxide-zinc oxide core-shell nanoparticles in C57BL/6 mice after repeated subcutaneous administration. In: Journal of Applied Toxicology. 2015 ; Vol. 35, No. 6. pp. 593-602.
@article{a7b8fea3cb2c4c3a98f03027fa387240,
title = "The toxicity and distribution of iron oxide-zinc oxide core-shell nanoparticles in C57BL/6 mice after repeated subcutaneous administration",
abstract = "Therapeutic cancer vaccines promote immune responses by delivering tumour-specific antigens. Recently, we developed iron oxide (Fe3O4)-zinc oxide (ZnO) core-shell nanoparticles (CSNPs) as carriers for antigen delivery into dendritic cells (DCs), and the CSNPs were injected subcutaneously into C57BL/6 mice to examine the systemic toxicity, tissue distribution and excretion of the CSNPs. The doses injected were 0, 4, 20 and 200mgkg-1 weekly for 4weeks. No significant changes were observed after the CSNPs administration with respect to mortality, clinical observations, body weight, food intake, water consumption, urinalysis, haematology, serum biochemistry,and organ weights. A dose-dependent increase in granulomatous inflammation was observed at the injection site of the CSNP-treated animals, but no other histopathological lesions in other organs could be attributed to the CSNPs. The Zn concentration, which is an indicator for CSNPs, was not significantly higher in the sampled tissues, urine, or faeces after the CSNP injection. In contrast, the Zn concentration at the subcutaneous skin of the site injected with the CSNPs increased in a dose-dependent manner, along with a macroscopic deposition of the CSNPs. The CSNP residue at the injection site resulted in a foreign body response with the appearance of macrophage infiltration, but otherwise did not show any systemic distribution or toxicity at up to 200mgkg-1 during this study. In conclusion, CSNPs could be used as good antigen carriers for DC-based immunotherapy, although further study is needed to completely clear the residue of the CSNPs at the injection site.",
keywords = "Distribution, Excretion, Iron oxide-zinc oxide core-shell nanoparticles, Nanoparticle, Toxicity",
author = "Yun, {Jun Won} and Yoon, {Jung Hee} and Kang, {Byeong Cheol} and Cho, {Nam Hyuk} and Seok, {Seung Hyeok} and Min, {Seung Kee} and Min, {Ji Hyun} and Cho, {Jeong Hwan} and Young-geun Kim",
year = "2015",
month = "6",
day = "1",
doi = "10.1002/jat.3102",
language = "English",
volume = "35",
pages = "593--602",
journal = "Journal of Applied Toxicology",
issn = "0260-437X",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - The toxicity and distribution of iron oxide-zinc oxide core-shell nanoparticles in C57BL/6 mice after repeated subcutaneous administration

AU - Yun, Jun Won

AU - Yoon, Jung Hee

AU - Kang, Byeong Cheol

AU - Cho, Nam Hyuk

AU - Seok, Seung Hyeok

AU - Min, Seung Kee

AU - Min, Ji Hyun

AU - Cho, Jeong Hwan

AU - Kim, Young-geun

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Therapeutic cancer vaccines promote immune responses by delivering tumour-specific antigens. Recently, we developed iron oxide (Fe3O4)-zinc oxide (ZnO) core-shell nanoparticles (CSNPs) as carriers for antigen delivery into dendritic cells (DCs), and the CSNPs were injected subcutaneously into C57BL/6 mice to examine the systemic toxicity, tissue distribution and excretion of the CSNPs. The doses injected were 0, 4, 20 and 200mgkg-1 weekly for 4weeks. No significant changes were observed after the CSNPs administration with respect to mortality, clinical observations, body weight, food intake, water consumption, urinalysis, haematology, serum biochemistry,and organ weights. A dose-dependent increase in granulomatous inflammation was observed at the injection site of the CSNP-treated animals, but no other histopathological lesions in other organs could be attributed to the CSNPs. The Zn concentration, which is an indicator for CSNPs, was not significantly higher in the sampled tissues, urine, or faeces after the CSNP injection. In contrast, the Zn concentration at the subcutaneous skin of the site injected with the CSNPs increased in a dose-dependent manner, along with a macroscopic deposition of the CSNPs. The CSNP residue at the injection site resulted in a foreign body response with the appearance of macrophage infiltration, but otherwise did not show any systemic distribution or toxicity at up to 200mgkg-1 during this study. In conclusion, CSNPs could be used as good antigen carriers for DC-based immunotherapy, although further study is needed to completely clear the residue of the CSNPs at the injection site.

AB - Therapeutic cancer vaccines promote immune responses by delivering tumour-specific antigens. Recently, we developed iron oxide (Fe3O4)-zinc oxide (ZnO) core-shell nanoparticles (CSNPs) as carriers for antigen delivery into dendritic cells (DCs), and the CSNPs were injected subcutaneously into C57BL/6 mice to examine the systemic toxicity, tissue distribution and excretion of the CSNPs. The doses injected were 0, 4, 20 and 200mgkg-1 weekly for 4weeks. No significant changes were observed after the CSNPs administration with respect to mortality, clinical observations, body weight, food intake, water consumption, urinalysis, haematology, serum biochemistry,and organ weights. A dose-dependent increase in granulomatous inflammation was observed at the injection site of the CSNP-treated animals, but no other histopathological lesions in other organs could be attributed to the CSNPs. The Zn concentration, which is an indicator for CSNPs, was not significantly higher in the sampled tissues, urine, or faeces after the CSNP injection. In contrast, the Zn concentration at the subcutaneous skin of the site injected with the CSNPs increased in a dose-dependent manner, along with a macroscopic deposition of the CSNPs. The CSNP residue at the injection site resulted in a foreign body response with the appearance of macrophage infiltration, but otherwise did not show any systemic distribution or toxicity at up to 200mgkg-1 during this study. In conclusion, CSNPs could be used as good antigen carriers for DC-based immunotherapy, although further study is needed to completely clear the residue of the CSNPs at the injection site.

KW - Distribution

KW - Excretion

KW - Iron oxide-zinc oxide core-shell nanoparticles

KW - Nanoparticle

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84928208303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928208303&partnerID=8YFLogxK

U2 - 10.1002/jat.3102

DO - 10.1002/jat.3102

M3 - Article

C2 - 25572658

AN - SCOPUS:84928208303

VL - 35

SP - 593

EP - 602

JO - Journal of Applied Toxicology

JF - Journal of Applied Toxicology

SN - 0260-437X

IS - 6

ER -